within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG14_Ublituximab;
model Ublituximab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AG14;

  annotation(Documentation(
    info ="<html><body><p>Ublituximab is a chimeric anti-CD20 monoclonal antibody developed for the treatment of relapsing forms of multiple sclerosis (MS). It works by depleting B cells, which play a role in the pathogenesis of MS. Ublituximab is approved for the treatment of relapsing forms of MS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults with relapsing multiple sclerosis based on typical monoclonal antibody characteristics and public regulatory documents.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Ublituximab;
